Wim H.J. Kruit

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami et al. · The Lancet · 2008 · 642 citations

Medicine, Oncology, Pharmacotherapy +14

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Fernando Ulloa‐Montoya, Jamila Louahed, Benjamin Dizier et al. · Journal of Clinical Oncology · 2013 · 475 citations · Full text

Medicine, Immunology, Oncology +17

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

Alexander M.M. Eggermont, Stefan Suciu, Rona M. MacKie et al. · The Lancet · 2005 · 315 citations

Medicine, Oncology, Surgery +17

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori et al. · Journal of Clinical Oncology · 2012 · 282 citations · Full text

Medicine, Oncology, Immunotherapy +16

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Wim H.J. Kruit, Stefan Suciu, Brigitte Dréno et al. · Journal of Clinical Oncology · 2013 · 222 citations

Life Sciences, Immunology, Oncology +17